Truist Securities has revised its financial outlook for BridgeBio Pharma, Inc. (BBIO), increasing its price target to $95 and reiterating a 'Buy' recommendation. This decision stems from the company's impressive fourth-quarter performance, particularly the better-than-expected sales figures for its drug Attruby, which saw a significant surge in new patient enrollments. The positive sentiment is echoed across the financial community, with other major firms also adjusting their targets upwards, reflecting a growing confidence in BridgeBio's strategic direction and product pipeline.
On February 25, 2026, Truist analyst Danielle Brill announced the revised price target for BridgeBio Pharma, moving it from $86 to $95. The analyst highlighted the company's preliminary Q4 Attruby sales of $146 million, a substantial 35% increase from the previous quarter, exceeding market forecasts. This strong sales growth was primarily attributed to an accelerated pace of new patient additions, a trend that appears to be continuing into the current period. This consistent patient growth underscores the market's acceptance and the clinical efficacy of Attruby.
Concurrently, on the same day, Morgan Stanley's analyst Sean Laaman also adjusted his price target for BridgeBio Pharma upwards, from $96 to $98. This revision followed a comprehensive review of the company's fourth-quarter report and updated financial estimates, further solidifying the positive outlook from investment banks. These back-to-back target increases from prominent financial institutions suggest a strong consensus regarding BridgeBio's market potential.
BridgeBio Pharma, Inc. released its fourth-quarter earnings report on February 24, 2026, revealing an EPS of ($1.00), which was slightly below the consensus estimate of (67c). However, the company's revenue for the quarter stood at $154.18 million, comfortably exceeding the consensus estimate of $149.07 million. Neil Kumar, Co-Founder and CEO of BridgeBio, reflected on the company's achievements over the past decade, emphasizing three successful Phase 3 readouts delivered within a tight three-month window. Kumar expressed optimism that this scientific rigor and progress could lead to a portfolio of six approved products as the company concludes its first decade of operations.
BridgeBio Pharma is dedicated to the discovery, development, and delivery of innovative medicines tailored for patients suffering from genetic diseases. The company's focus on genetic conditions positions it in a specialized, high-growth sector of the pharmaceutical industry. The recent financial updates and analyst adjustments reflect a positive trajectory for BBIO, signaling potential for continued expansion and success in its therapeutic areas.